The AMPD2 Knockout A-549 Polyclonal Cells are a population of human A-549 lung adenocarcinoma epithelial cells with CRISPR/Cas9-mediated disruption of AMPD2. This polyclonal pool contains a heterogeneous mixture of loss-of-function alleles, providing a genetically diverse model that avoids single-cell clonal selection bottlenecks. This format is ideal for functional genomics and screening applications where population-level phenotypes are of interest.
The A-549 cell line, established from a 58-year-old Caucasian male with lung carcinoma, is a widely used model of alveolar type II pulmonary epithelium. It is extensively employed in cancer biology and drug screening due to its capacity to recapitulate non-small-cell lung cancer characteristics, including dysregulated proliferation and metabolic reprogramming. The robust growth and epithelial origin of A-549 cells make them well-suited for generating knockout derivatives for diverse in vitro assays.
AMPD2 catalyzes the deamination of AMP to IMP in the purine nucleotide cycle, a critical step that regulates adenine nucleotide pools and energy charge. Its activity is controlled by upstream regulators such as c-Myc, the AMP/ATP ratio, and allosteric effectors like ATP, GTP, and inorganic phosphate. Downstream, IMP serves as a substrate for adenylosuccinate synthetase and adenylosuccinate lyase and feeds into purine salvage via HPRT and APRT. AMPD2 function also influences AMPK signaling and adenosine receptor pathways. In this knockout model, disruption of AMPD2 impairs AMP-to-IMP conversion, altering purine recycling and energy homeostasis.
In A-549 lung cancer cells, loss of AMPD2 may perturb nucleotide metabolism, affecting proliferation and stress responses. Given the reliance of cancer cells on balanced nucleotide pools, this model can reveal metabolic vulnerabilities linked to AMPD2 deficiency. The polyclonal design allows capturing a range of fitness effects and partial loss-of-function states, providing a powerful system to study genotype?Cphenotype relationships in the context of lung adenocarcinoma.
Researchers can apply this model to purine metabolism studies using HPLC- or LC?CMS-based nucleotide profiling and AMP deaminase activity assays. It is also valuable for cancer cell metabolism analyses via metabolic flux and proliferation assays, as well as for drug sensitivity screening. The population format is well-suited for CRISPR polyclonal pool functional genomics. Additionally, the cells serve as a human model for Pontocerebellar hypoplasia type 9, a neurodevelopmental disorder linked to AMPD2 mutations. Routine characterization can be done by western blotting and RT-qPCR. For further information and ordering, please contact Ascent Research.
